Given this, targeting the SCL-LMO1/2 or LYL1-LMO1/2 [10] protein–protein interaction by small molecule inhibitors might represent an elegant new therapeutic approach to constrain self-renewing capacity of both leukemic and pre-leukemic cancer stem cells in T-ALL. Here, LYL1 is linked to acute lymphoblastic leukemia.